The Carlyle Group to Acquire French Insurance Software Vendor Prima Solutions
Global alternative asset manager The Carlyle Group (NASDAQ:CG) today announced it has signed an agreement to acquire French insurance software vendor Prima Solutions, in partnership with its management team.
This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20170906005432/en/
The transaction is expected to close on September 30th, 2017, subject to approval from the relevant authorities. Carlyle Europe Technology Partners III, a €657m Carlyle fund focused on European technology, media and telecommunications (TMT) companies, will make the investment. Financial terms are not disclosed.
Prima Solutions is a French software vendor that designs, develops and markets software exclusively for insurance providers. Founded in 2000 by Hugues Delannoy, co-founder of the Assurland.com insurance comparison website, Prima Solutions offers modular digital applications to help insurance companies optimize customer relations and insurance policy management.
Headquartered in Paris, with a presence in European and international markets, Prima Solutions has 200 employees and has grown more than 80% per year since 2013, reaching turnover of more than €20 million in 2017. The company’s sales momentum and innovative products and services make it the natural choice for insurance providers facing a range of operational challenges, including the introduction of new distribution models and digital customer relationship platforms and the creation of innovative products. Prima Solutions’ customers include Allianz, AXA, MAIF, Société Générale, PSA Insurance and Hiscox.
Following this acquisition, Prima Solutions will continue to be led by the current leadership team, including Founder and President Hugues Delannoy, and CEO Rodolphe Peim.
Vladimir Lasocki, Managing Director of the Carlyle Europe Technology Partners team, said: “Prima Solutions has built up a solid foundation for continued growth in Europe and internationally. In less than four years, the company has become a reference in its market in Western Europe. The management team has shown it can create strong and promising sales momentum and growth. We look forward to working with Hugues, Rodolphe and their team to actively support Prima Solutions on its expansion path.”
Charles Villet, Associate Director of the Carlyle Europe Technology Partners team, added: “We are impressed with the range of solutions developed by Prima Solutions. The insurance sector is experiencing – and will continue to experience – a profound digital transformation to stay competitive. Prima Solutions has positioned itself as a key player in this market.”
Prima Solutions’ Chairman Hugues Delannoy commented: “We are delighted to join forces with Carlyle. This partnership marks a pivotal step in Prima Solutions’ development. Carlyle’s in-depth understanding and extensive experience in the insurance sector will help us rapidly boost our international sales growth. Today’s insurance providers are prepared for the strategic challenges posed by digital technology, and our tried-and-tested platform is optimally poised to meet and exceed their expectations.”
Advisors on the transaction
- Legal Advisor (Buyside): DLA Piper
- Financial due diligence advisor (Buyside): Accuracy
- Strategic due diligence advisor (Buyside): L.E.K
- Technology due diligence advisor (Buyside): Intuitus
- M&A Advisor (Buyside): William Blair
- Legal Advisor (Sellside) Hoche Avocats
- Financial due diligence advisor (Sellside): E&Y
- M&A Advisor (Sellside): Bryan Garnier
About Prima Solutions
Prima Solutions delivers the software platform Property and Casualty insurers need to gain in agility and succeed in a time of rapid industry change. Full web, modular, multilingual and available in SaaS mode, Prima Insure™ addresses the whole life cycle of an insurance policy: distribution; underwriting; contract; claims and financial management. More than 20 Property and Casualty insurers, including Allianz, AXA, Société Générale Insurance, PSA Insurance, CoverLife, Galian, Groupama, Hiscox, Mutuelle des Motards or Gras Savoye Willis, have already selected Prima Insure™. Prima Solutions is a member of ACORD.
About The Carlyle Group
The Carlyle Group (NASDAQ:CG) is a global alternative asset manager with $170 billion of assets under management across 299 investment vehicles as of June 30, 2017. Carlyle’s purpose is to invest wisely and create value on behalf of its investors, many of whom are public pensions. Carlyle invests across four segments – Corporate Private Equity, Real Assets, Global Market Strategies and Investment Solutions – in Africa, Asia, Australia, Europe, the Middle East, North America and South America. Carlyle has expertise in various industries, including: aerospace, defense & government services, consumer & retail, energy & power, financial services, healthcare, industrial, infrastructure, real estate, technology & business services, telecommunications & media and transportation. The Carlyle Group employs more than 1,550 people in 31 offices across six continents.
Steele&Holt (The Carlyle Group)
Daphne Claude & Dominic Riding
+33(0) 6 66 58 81 92 / +33(0) 6 57 48 83 24
+44(0)207 894 1632 / +44(0)7429 421 037
+33(0) 6 24 04 23 39
Om Business Wire
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
Shell, bio-bean and Coffee-Drinkers Collaborate to Help Power London’s Buses20.11.2017 00:01 | Pressemelding
Shell and bio-bean announce that together they are helping to power some of London’s buses using a biofuel made partly from waste coffee grounds. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171119005060/en/ Shell and bio-bean announce that together they are helping to power some of London's buses using a biofuel made partly from waste coffee grounds (Photo: Business Wire) The B20 biofuel contains a 20% bio-component which contains part coffee oil. The biofuel is being added to the London bus fuel supply chain and will help to power some of the buses; without need for modification. Biofuel provides a cleaner, more sustainable energy solution for buses across London’s network by decreasing emissions1. “Our Coffee Logs have already become the fuel of choice for households looking for a
Samsung Bioepis Receives Regulatory Approval for Europe's First Trastuzumab Biosimilar, ONTRUZANT®19.11.2017 22:21 | Pressemelding
Samsung Bioepis Co., Ltd. today announced the European Commission’s (EC) marketing authorization of ONTRUZANT ® , a biosimilar referencing Herceptin ® (trastuzumab), for the treatment of early breast cancer, metastatic breast cancer and metastatic gastric cancer. ONTRUZANT ® is the first trastuzumab biosimilar to receive regulatory approval in Europe. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171119005066/en/ Christopher Hansung Ko, President & CEO of Samsung Bioepis. (Photo: Business Wire) The EC approval of ONTRUZANT ® applies to all 28 European Union (EU) member states and the European Economic Area (EEA) member states of Norway, Iceland and Liechtenstein. ONTRUZANT ® will be commercial
Cancer Patients, Survivors, Supporters and Caregivers Undertake UAE's First Relay for Life19.11.2017 16:31 | Pressemelding
Sharjah, the third largest of the United Arab Emirate’s seven emirates, was the host for the MENA region’s first ever ‘Global Relay for Life,’ (RFL) a 24-hour walkathon that is the biggest fundraising event for cancer in the world. Conducted in conjunction with the American Cancer Society, the event was organised by Friends of Cancer Patients (FoCP), a non-profit organisation that supports cancer patients and their families. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171119005048/en/ During MENA's first Global Relay For Life walkathon - Source: Friends of Cancer Patients Taking place November 17-18 at the American University Sharjah, the inaugural UAE RFL saw more than 2,000 relayers participating in the overnight event, with a large number of individuals and institutions involved including 52 sch
New Data Show Benefit of Tagrisso in Patients with EGFR-mutated Non-small Cell Lung Cancer and Central Nervous System Metastases18.11.2017 23:00 | Pressemelding
AstraZeneca today presented new data from a subgroup analysis of the Phase III FLAURA trial, which explored osimertinib as 1st-line therapy in patients with locally advanced or metastatic epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC). Results presented at the ESMO Asia 2017 Congress in Singapore showed that patients with central nervous system (CNS) metastases at baseline had a higher objective response rate with their brain metastasis and suggest a lower risk of CNS progression when treated with osimertinib, a third-generation, irreversible EGFR tyrosine kinase inhibitor (TKI), versus current standard-of-care EGFR-TKIs (erlotinib or gefitinib) [Abstract LBA5].1 The analysis included patients with ≥1 measurable and/or non-measurable CNS lesion present on baseline scan (as assessed by blinded independent central review), accounting for 23
New England Journal of Medicine Publishes Results of Phase III FLAURA Trial in the 1st-Line Treatment of EGFR-mutated Non-small Cell Lung Cancer18.11.2017 18:20 | Pressemelding
AstraZeneca today announced that the New England Journal of Medicine has published the positive results from the Phase III FLAURA trial which provide data for Tagrisso’s (osimertinib) use in the 1st-line treatment of adult patients with locally advanced or metastatic epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC).1 The trial showed a statistically significant, clinically meaningful progression-free survival (PFS) advantage for osimertinib, a third-generation, irreversible EGFR tyrosine kinase inhibitor (TKI), compared with current 1st-line EGFR-TKIs, erlotinib or gefitinib.1 This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171118005044/en/ Dr. Suresh S. Ramalingam, Principal Investigator of the FLAURA trial, from the Winship Cancer Institute
Much-Anticipated CHTF 2017 Top 10 Products Are Unveiled18.11.2017 09:11 | Pressemelding
The 19th China Hi-Tech Fair (CHTF 2017), with the theme of “Innovation-Driven Development and Supply Quality Upgrade”, is taking place from November 16 to 21 at Shenzhen Convention and Exhibition Center. On the afternoon of November 10, the CHTF 2017 Top 10 Products were unveiled at the awards ceremony by Mr. Gao Zimin, Vice Mayor of Shenzhen City. A total of 322 entries competed for the honor Top 10 Products, and the voting lasted nearly 3 months. 60 candidate products in the fields of new energy, 3D print, flexible display, life sciences, unmanned vehicles and AI were shortlisted by the organizer, experts and media representatives and went for open voting online. The final Top 10 Products all represent the most advanced technologies in their respective sectors: the water-making device that can make water out of air, the smart sportswear that can monitor heartbeat and other
I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.Besøk vårt presserom